Saturday, 27 June 2020

Special Update 27/06/2020 Is Covid-19 Out Of Control?


Baltic Dry Index. 1749 +11  Brent Crude 41.02
Spot Gold 1761

Covid-19 cases 13/06/20 World 7,783,275
Deaths 431,168

Covid-19 cases 27/06/20 World 10,068,510
Deaths 500,131

“It is a capital mistake to theorize before one has data. Insensibly one begins to twist facts to suit theories, instead of theories to suit facts.”

Sir Arthur Conan Doyle, A Scandal in Bohemia

Reuters posits for the week ahead, “But as North Korea’s military threats ebb and flow and troops amass on both sides of a disputed part of the Indo-Chinese border, geopolitics will likely trump other factors.” I think what happens next in the coronavirus crisis will trump geopolitics. New cases, undercounted, are running at a million a week.

From the USA to India, Covid-19 cases are soaring.  With major national holidays in Canada and the USA next week, increased infection is a foreseeable result.

Worse this comes on top of all the recent civil unrest and demonstrations and rioting, that’s already contributing to a rise in US cases among the under 35s.

Short of a war, what happens in the next 4-6 weeks in the coronavirus crisis is likely to trump all else.

If we don’t get on top of the rise in new infections, globally and in the USA, our highly integrated global economy will suffer from severe drag.

There will be no “V” shaped recovery, not even a “U” shaped recovery. Just a muddle along global economy, increasingly running into rising unemployment, rising bankruptcies, rising real estate distress, rising global supply chain stress, and after a brief retail sales rebound from lock down relief, a severe consumer demand shock.

With all this uncertainty ahead, the prudent will remain in the safety of cash and precious metals. The casinos are for the feckless and reckless.

Take Five: World stocks' 2020 rollercoaster ride rumbles on

June 26, 2020 / 1:28 PM
World stocks have been on a rollercoaster ride in the first half of 2020. Having slumped 35% from Feb. 20 to March 23, they are now within 10% of February’s record highs thanks to lashings of fiscal stimulus, interest rates slashed to 0% or below in most major economies, and massive amounts of QE. Borrowing costs for high-grade U.S. companies have in fact fallen below January levels.

So what happens over the rest of the year? Much depends on whether another coronavirus wave comes crashing down, further testing policymakers. And if an effective treatment or a vaccine is found, the severest global recession in living memory could also turn out to be the shortest.

Nevertheless, the crisis has exposed weaknesses such as companies’ high debt levels and their over-reliance on share buybacks.

Asian market anxiety levels look set to rise another notch in coming days due to geopolitical tensions.

Hong Kong will be in the Chinese parliament’s sights when it meets on June 28-30 to finalise a security law aimed at tackling separatism, subversion, terrorism and collusion with foreign forces.

After a year of sometimes violent anti-government and anti-Beijing protests, the focus is on how far-reaching the law is, what activities constitute such crimes and what the punishment would be. Investors also want to know whether the laws will be retroactive or create new avenues for asset seizures.

China and much of Asia will also publish manufacturing surveys. But as North Korea’s military threats ebb and flow and troops amass on both sides of a disputed part of the Indo-Chinese border, geopolitics will likely trump other factors.
More

‘Make no mistake…the pandemic morphed into a Depression-like crisis,’ says UCLA economist, who predicts U.S. economy won’t recover from coronavirus until 2023

Published: June 25, 2020 at 4:47 p.m. ET
The road to recovery for the U.S. economy from the COVID-19 pandemic could be a very long one, predicts David Shulman, senior economist at UCLA Anderson School of Management in a recently published quarterly research report.

Shulman said the current economic damage created by lockdowns and closures that have been put in place for months goes well beyond a garden-variety economic recession. “To call this crisis a recession is a misnomer,” he warned.

“Make no mistake, the public health crisis of the pandemic morphed into a depression-like crisis in the economy,” he wrote. Shulman is forecasting a 42% annual rate of decline in real gross domestic product for the current quarter, which he says will be followed by a so-called “Nike swoosh,” or more gradual recovery “that won’t return the level of output to prior fourth quarter of 2019 peak until early 2023.”

“Too many small businesses will fail, and millions of jobs in restaurants and personal service firms will disappear,” Shulman wrote. “For too many workers, the recession will linger on well past the official end date of the depression.”

Shulman’s forecast comes as the U.S. counted 34,700 new confirmed cases on Wednesday, according to the Associated Press, the highest level since a late April peak number of 36,400. While New York and neighboring states have succeeded in flattening their infection curve, 29 states still see increasing cases over the last 14 days, according to a New York Times tracker.

The resurgence of the viral outbreak, which has infected 9.5 million people world-wide, has delayed business reopenings in many parts of the U.S. and compelled Texas to pause its reopening plans. Texas Gov. Greg Abbott said he froze the reopening of the state in response to the spike in cases of COVID-19 and hospitalizations.

Shulman told MarketWatch that when he prepared the economic forecast, the viral outbreak looked to be more contained and acknowledges that his grim prediction could be even worse if the virus gets out of control in many of the hotspot states.

“When we did this report, we assumed the path was getting better,” he said. “This big acceleration [in cases] happened in the past week,” he added. The economist said that the surge in infections and hospitalizations could lead individuals to impose their own lockdowns, notwithstanding any put in place by local and federal governments.
More

‘Black Swan’ author says if investors don’t use a ‘tail hedge,’ he recommends ‘not being in the market’—‘We’re facing a huge amount of uncertainty


Published: June 26, 2020 at 4:09 p.m. ET
That’s “Black Swan: The Impact of the Highly Improbable” author Nassim Nicholas Taleb offering his view on the risks swirling in the market and a growing lack of clarity about the future in the era of a deadly pandemic that has created a public-health and economic crisis.

Speaking during an interview on CNBC on Friday, the popular author, shared the notion that investors should be hedged against so-called “tail risk,” which refers to extreme events that have a low probability of happening in a distribution of outcomes. Taleb has spent his career chronicling so-called “tail risk” events, which have a tiny probability of occurrence, but nonetheless take place more often than one would guess, and therefore often are underestimated by the broader investment community.

Taleb said the current market landscape, perhaps, has amplified uncertainties, even if the stock market has been mostly rising, despite signs of a spreading COVID-19 pandemic that is re-intensifying in places and threatening to de-rail projections for a “V-shaped,” or quick, economic recovery.

“We are printing money like there’s no tomorrow,” Taleb said, referencing the Federal Reserve’s efforts to ease the financial pain of the epidemic by delivering trillions of stimulus to the market. The Fed also cut interest rates to a superlow range of 0% and 0.25% back in March, and may not have a lot of room to further ease the economic pain of the viral outbreak and other problems that could arise amid this crisis.

“And COVID seems to be there even if the pandemic…dies down, you will still have people cautious enough that it will impact a lot of industries,” he said.
More

In Covid-19 news, it was a bad news week all round. Even when/if we get a viable vaccine, there are big logistical problems to overcome in distributing it.

Coronavirus cases in India cross 500,000 as big cities reel from surge

June 27, 2020 / 5:34 AM
NEW DELHI (Reuters) - India reported over 17,000 new coronavirus cases over the last 24 hours, pushing the country’s total above 500,000, federal health ministry data showed on Saturday, with infections surging in major cities including the capital New Delhi.

India has the world’s fourth-biggest outbreak of the virus that causes COVID-19, below only the United States, Brazil and Russia in confirmed infections, according to a Reuters tally.

Infections are expected to continue rising steadily in India. Experts advising the federal government say the authorities should now prioritise reducing mortality over containing the spread of the virus.

“Our focus should be on preventing deaths and not really getting bogged down because of the numbers. Numbers are going to increase,” said Dr Manoj Murhekar, a member of India’s main coronavirus task force and director of the National Institute of Epidemiology.

The COV-IND-19 study group, led by Bhramar Mukherjee, a biostatistics professor from the University of Michigan, forecasts that India could see between 770,000 and 925,000 cases by July 15.

As infections mount swiftly and hospitals become stretched, some cities like New Delhi are scrambling to build temporary facilities with thousands of beds to quarantine and treat COVID-19 patients.
More

Severe COVID-19 can damage the brain, preliminary study finds

June 25, 2020 / 11:37 PM
LONDON (Reuters) - A preliminary study of patients hospitalised with COVID-19 has found the disease can damage the brain, causing complications such as stroke, inflammation, psychosis and dementia-like symptoms in some severe cases.

The findings are the first detailed look at a range of neurological complications of COVID-19, the researchers said, and underline a need for larger studies to find the mechanisms behind them and assist the search for treatments.

“This (is) an important snapshot of the brain-related complications of COVID-19 in hospitalised patients. It is critically important that we continue to collect this information to really understand this virus fully,” said Sarah Pett, a University College London professor who co-led the work.

The study, published in the Lancet Psychiatry journal on Thursday, looked in detail at 125 cases from across the UK. Co-lead researcher Benedict Michael, from Liverpool University, said it was important to note that it focused on severe cases.

Data was collected between April 2 and April 26 - when the disease was spreading exponentially in the UK.

The most common brain complication seen was stroke, which was reported in 77 of 125 patients. Of these, most were in patients over 60, and most were caused by a blood clot in the brain, known as an ischaemic stroke.

The study also found that 39 of the 125 patients showed signs of confusion or changes in behaviour reflecting an altered mental state. Of these, nine had unspecified brain dysfunction, known as encephalopathy, and seven had inflammation of the brain, or encephalitis.
More

Vaccine Makers Turn to Microchip Tech to Beat Glass Shortages

We'll need millions of vials to distribute the vaccine. The US government thinks manufacturing methods from the semiconductor industry can help.
06.26.2020 07:00 AM


----But the science of producing a safe, broadly-effective vaccine is just the first step. Actually exiting the pandemic will require the subsequent manufacturing of the best-performing ones, bottling them up, shipping them around the world, and doling them out to vulnerable populations. In the case of Covid-19, that’s pretty much everybody on the planet, which means making somewhere between 7 and 15 billion doses. (Many vaccines have to be given in two doses—a primer and a boost.) No one has ever tried to do that before. And as these historic efforts to produce an unprecedented number of shots in so short a time are ramping up, vaccine makers say the biggest bottleneck they’re encountering is a cruelly literal one.

“The challenge is not making the vaccine itself, it’s filling vials. There just aren’t enough vials in the world,” Pascal Soriot, the executive director and CEO of AstraZeneca, told reporters in a press briefing last month. AstraZeneca is working with the University of Oxford on one of the frontrunners in the Covid-19 vaccine race. But it’s just one of many pharmaceutical firms scrambling to source containers for that critical bottling step. Executives from AG Schott, one of the world’s major medical glass producers, recently told The Wall Street Journal that the company has received requests from vaccine makers for a billion vials—double what it can produce this year.

Medical glass is strong but it’s still breakable. So manufacturers typically don’t make lots of excess inventory. They make what pharmaceutical companies order. And pharmaceutical companies typically don’t put in those orders until they know they’ve got a vaccine that works, plus distribution contracts in place to provide bulk doses to customers. But nothing about these times is typical. Governments and nonprofits are pumping money into ramping up vaccine manufacturing capacity in parallel with clinical testing so that individual companies don’t have to assume so much risk for paying for trials and production themselves. They’re also experimenting with nanotechnology borrowed from the semiconductor industry to make an end- run around traditional forms of glass.

In the US, this concerted effort has been dubbed Operation Warp Speed. The US government’s Biomedical Advanced Research and Development Authority, or Barda, has so far invested approximately $2.2 billion in Covid-19 vaccine makers, including AstraZeneca, Johnson & Johnson, and Moderna Therapeutics, according to the agency’s portfolio. In partnership with the National Institutes of Health, these companies are planning to start Phase 3 trials this summer. Their goal is to not have a long gap between the time they prove that a vaccine works and when they can start making it available to lots of people.

Avoiding a scenario in which an effective vaccine gets rationed to a chosen few also means overcoming the glass bottle shortage. The issue was on the US government’s radar early on in the pandemic, according to a 60-page whistleblower complaint filed by Rick Bright, the former director of Barda who was abruptly ousted from his post in April. In it, Bright claimed that between January and March he repeatedly and unsuccessfully urged administration officials to secure supplies needed for a mass immunization campaign, including needles, syringes, and glass vials.

----But closing the glass gap will take time. Supply chain experts say that booting up a new manufacturing site capable of making an additional 100 to 500 million vials per year will take at least six to eight months. That’s if glass vial makers can get their hands on the raw materials to feed those production lines. Medical glass has to be able to withstand huge temperature swings and keep chemically-finicky vaccine components stable. Making it requires melting down an especially angular species of sand found in beaches and riverbeds, with grains jagged enough that they lock together to form a sturdy glass solid. This type of sand is in such high demand—for use in everything from solar panels to concrete—that it’s sparked a violent boom in illegal sand mining in recent years.
More
Finally, in the strange Case of the ‘Dog That Didn’t Bark, the EU moves to close the stable doors, now that 4 billion Euros or so, have bolted to Euro heaven. Do “oversight” and “Wirecard” go together in a single English sentence?  

Germany’s regulator BaFin, is one of the few organisations on planet Earth, that makes the Trump administration look like joined up adult government. I wonder if they’d like to buy my New York bridge? Better yet, maybe I can sell it to Softbank.

“Is there any point to which you would wish to draw my attention?' 
'To the curious incident of the dog in the day and night-time.'
'The dog did nothing in the day and night-time.'
'That was the curious incident,' remarked the European Commission.”

With apologies to Sir Arthur Conan Doyle, and Silver Blaze.

German oversight of Wirecard to be examined by EU watchdog

June 26, 2020 / 7:19 AM
BRUSSELS (Reuters) - The European Commission will ask its markets watchdog to investigate whether German financial regulator BaFin failed in its supervision of payments company Wirecard.
Germany’s Wirecard (WDIG.DE) collapsed on Thursday owing creditors almost $4 billion.

Depending on that preliminary probe’s results, the Commission could launch an investigation into whether BaFin broke EU law on financial reporting, Valdis Dombrovskis, the Commission’s executive vice president, told the Financial Times newspaper in an interview.

“We will be asking ESMA (the European Securities and Markets Authority) to investigate whether there have been supervisory failures, and if so, to set out a possible course of action,” Dombrovskis told the newspaper.

“We need to clarify what went wrong,” he said, adding he would set a mid-July deadline for ESMA to reply.

ESMA confirmed that it had been asked to look at how BaFin enforced the EU’s transparency directive which covers financial reporting requirements for listed companies.

“We have received a request from the European Commission for a fact-finding analysis of events leading up to the collapse of Wirecard and supervisory responses to the events,” an ESMA spokesman said.

Dombrovskis could use the findings from ESMA’s analysis to order a formal “breach of union law” investigation, requiring BaFin to provide information to ESMA.

If a breach is found, BaFin could be ordered by Brussels to make changes to its practices, an embarrassing situation for a national regulator.

The EU’s transparency rules aim to ensure that investors are given the proper flow of information about a company.

SoftBank plans to sue EY over Wirecard scandal - Der Spiegel

June 26, 2020 / 10:47 AM
BERLIN (Reuters) - SoftBank is planning to sue accounting firm EY over its role in the scandal involving German payments company Wirecard, news magazine Der Spiegel reported on Friday, citing sources close to the Japanese company.

Wirecard collapsed on Thursday owing creditors almost $4 billion (£3.2 billion) after disclosing a gaping hole in its books that its longtime auditor EY blamed on a sophisticated global fraud.

SoftBank put money into Wirecard last year.

SoftBank did not respond to a request for immediate comment.

Wirecard Shows Life at Hedge Funds can be Agony

Short sellers deserve our appreciation, not scorn, for helping root out corporate frauds.
By Chris Bryant
June 25, 2020, 10:25 AM GMT+1
You know the German finance world has been shaken when even the president of BaFin, the country’s conservative stock market regulator, showers praise on hedge funds. Apologizing for Germany’s failure to prevent a massive accounting fraud at electronic-payments group Wirecard AG, Felix Hufeld paid belated tribute this week to those “journalists, analysts or yes, let it be short sellers, who have been digging out inconsistencies persistently and rigorously.”

---- Things rarely pan out smoothly when doing this, but the tribulations of shorting Wirecard, which started filing for insolvency on Thursday, belong in a category of their own. With an army of credulous equity analysts and fund managers cheering the stock higher, and an auditor happy to sign off the accounts, Wirecard was a mightily difficult beast for the shorts to slay. Despite all kinds of warning signs, investors “gave the company the benefit of the doubt over and over and over again,” Jim Chanos, the founder of hedge fund Kynikos Associates — who helped expose Enron’s accounting crimes — told Bloomberg Television.

---- When Wirecard admitted this week that four-fifths of its net cash probably didn’t exist, Coatue Management, TCI Fund Management, Greenvale Capital and Darsana Capital Partners were among the funds with the largest short positions.

But, believe it or not, for many short sellers it’s not only about the money. They perform an important though rarely acknowledged function in rooting out corporate malfeasance through countless hours of detective work, often at great expense. As with Wirecard, they’re sometimes happy to share their concerns with regulators. “Short selling can be a valuable indicator of fraud and misrepresentation,” Fahmi Quadir of Safkhet Capital, a prominent Wirecard short, wrote in a letter to BaFin last year after the regulator took the rare step of banning the shorting of the German company’s stock.
More

Now comes, I suspect, the most interesting part of this still growing European scandal. As forensic accountants pour over the books, who moved what money for whom, and why? Any alphabet soups involved do you think?

This weekend’s musical diversion.  Vivaldi again, or is it? The RV Index lists this as “doubtful.” If it’s a fake, it’s more Vivaldi than Vivaldi! You decide, Vivaldi or not Vivaldi.

A. VIVALDI: Concerto for Violin, Organ, Strings and B.C. in F major RV 542, La Serenissima


“Crime is common. Logic is rare.” 

Sir Arthur Conan Doyle, The Adventure of the Copper Beeches

The Monthly Coppock Indicators finished May.

DJIA: 25,383 +12 Down. NASDAQ: 9,490 +178 Up. SP500: 3,044 +83 Down.

The NASDAQ has rebounded to up. The S&P and the DJIA remain down. But the game is now totally rigged by the Fed.

No comments:

Post a Comment